The two companies are working together to develop AT-527, an orally administered, direct-acting antiviral therapy for patients diagnosed with COVID-19.
In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
Drugs currently being used to treat psychosis or depression may be able to treat emerging viruses, according to new research led by the University of Leeds.
A team of researchers has modified a lectin protein found in bananas to diminish its inflammatory properties, potentially setting it on the path to use as an antiviral.
As the death toll from MERS in South Korea edged to two dozen scientists there say the outbreak is different from in Saudi Arabia and also from its the related virus SARS.
Novasep has signed a €4.7m ($5.4m) agreement with Celladon, a clinical-stage biotechnology company, to prepare to supply the drug substance for the heart failure treatment Mydicar.
NanoViricides' nanotech drug delivery platform has the potential to eliminate viruses, the firm says as construction began on a manufacturing facility to support upcoming clinical trials.
Sanofi has inked a deal that will see it contract manufacture immunotherapy products for Transgene using a new platform developed by the two companies.
Sartorius Stedim Biotech has teamed up with Wuxi AppTec to help
companies remove some of the strain of carrying out viral clearance
testing, which for large biopharmaceutical companies can carry a
price tag of up to $1m a year.
A new 'map' that depicts the interactions between proteins from
pathogens and humans could help explain how viruses and bacteria
manage to trick victim cells into carrying out their dirty work.
Integrated DNA Technologies (IDT) has launched LabLinker, a free
online system for sharing genome sequence data and even share
shipping costs of orders.
US biopharmaceutical company CytoGenix has announced breaking
ground on a new $3.8m facility to expand the company's
manufacturing capability of synthetic DNA.
Researchers have characterised a component of the severe acquired
respiratory syndrome (SARS) virus that looks to be a promising
target for new anti-SARS virus drugs.
Scientists have made a remarkable discovery that could open up new
avenues in drug development resulting in novel therapies for the
treatment of poxviruses such as variola virus, the cause of
smallpox.
British gene therapy firm Oxford Biomedica has licensed its VSV-G
viral envelope technology for gene delivery to American biotech
company VIRxSYS which hopes it can use it to successfully produce
its promising anti-HIV/AIDS product...
Researchers are to develop new computational diagnostic methods for
key viral pathogens, which are set to make the storage, retrieval,
and exchange of molecular and diagnostic data on viral pathogens
more efficient and effective.
Large Scale Biology Corporation (LSBC) along with its subsidiaries
Bioprocessing and Predictive Diagnostics, has now filed for Chapter
11 bankruptcy protection after going bust last month.
US scientists have claimed to have developed the next generation of
effective viral-based therapies for cancer in which 'terminator'
viruses are deployed to destroy primary tumours.
US firms Large Scale Biology Corp and privately-held Planet
Biotechnology have expanded their biomanufacturing program to
extract and purify the latter's lead product, CaroRx, a plant-made
antibody to control dental caries.
An ionic silver complex designed for human antimicrobial use has
received a US patent, in a move that could well see increased usage
of this technology that exhibits broad-spectrum antimicrobial
qualities as well as displaying a lack...
An opportunity to develop drugs by targeting a recently discovered,
and potentially vulnerable, intermediate stage of the viral life
cycle, could result in a new pharmaceutical treatment in the fight
against HIV and other similar...
Researchers have discovered that a certain virus appears to cloak
itself with a recently discovered gene-silencing device to evade
detection and destruction by immune cells. The study is the first
to show how a virus uses the gene...
Qiagen has acquired the PCR diagnostics company Artus, in a move
that now allows Qiagen to offer preanalytical sample preparation
and diagnostic assay solutions to its partners in molecular
diagnostics. The acquisition further allows...
REPLICor is developing a broad spectrum antiviral drug, which has
the broadest spectrum of activity in vitro ever reported for a
single chemical entity and has proved to have a devastating action
on the herpes viruses, influenza and...
Qiagen has launched an automated viral DNA and RNA purification
solution that provides improved sensitivity in purification and
detection of viral DNA and RNA from serum, plasma, and cell-free
body fluids.
The first molecular-scale images of DNA binding to an adenovirus
enzyme, a crucial step for a virus to cause infection, have been
produced, which shows how binding to DNA may stimulate the enzyme,
aiding to the design of new antiviral...
A small German company has developed a new drug delivery technology
that can transport active drugs into the interior of cells by an
intrinsic, active mechanism.
Scientists studying vaccinia virus, a close relative of smallpox,
have discovered that a gene necessary for virus replication also
plays a key role in turning off inflammation, a crucial antiviral
immune response of host cells.
Shares in Cobra Biomanufacturing of the UK fell 30 per cent
yesterday after the contract manufacturer of proteins, DNA and
viruses gave a warning on profits.
German biopharmaceutical company Medigene has been granted a US
patent covering a specific manufacturing process for viruses suited
for the use in therapies and research.
MediGene is relocating the entire research department of its US
subsidiary to Germany, delighting those who lament the "brain
drain" of scientific talent flowing in the other direction
